MedTrace Logo

Using ctDNA to Determine Therapies for Lung Cancer

NCT04966663 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-12-18

No results posted yet for this study

Summary

This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

Conditions

  • Non Small Cell Lung Cancer
  • Complete Surgical Resection
  • Circulating Tumor DNA

Interventions

DRUG

Nivolumab

Antineoplastic agent

DRUG

Pemetrexed

Antineoplastic agent

DRUG

Gemcitabine

Antineoplastic agent

DRUG

Cisplatin

Antineoplastic agent

DRUG

Carboplatin

Antineoplastic agent

PROCEDURE

ctDNA blood test

Blood will be collected for ctDNA testing

Sponsors & Collaborators

Principal Investigators

  • Natasha Leighl · Princess Margaret Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2026-08-01
Completion
2026-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966663 on ClinicalTrials.gov